This investment product primarily channels its resources, typically committing a minimum of 95% of its net assets, into American Depositary Receipts (ADRs) that represent the B Shares of Novo Nordisk A/S. It's crucial to understand that direct investment in the company's underlying shares is not part of this series' strategy. Additionally, the fund is structured as non-diversified, indicating a concentrated portfolio.

Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged

The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of the Novo Nordisk A/S (B Shares) (the “Company”). The series will not invest directly in the company. The fund is non-diversified.

NVOH Holdings & Sector Breakdown

NVOH Holdings & Sector Breakdown